Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.
Scambia G, Villalobos Valencia R, Colombo N, Cibula D, Leath CA 3rd, Bidziński M, Kim JW, Nam JH, Madry R, Hernández C, Mora PAR, Ryu SY, Ah-See ML, Lowe ES, Lukashchuk N, Carter D, Penson RT. Scambia G, et al. Among authors: leath ca 3rd. J Clin Oncol. 2024 Dec 12:JCO2400933. doi: 10.1200/JCO.24.00933. Online ahead of print. J Clin Oncol. 2024. PMID: 39668137
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
Lee JM, Brady MF, Miller A, Moore RG, MacKay H, McNally L, Lea J, Street D, Lheureux S, McDonald ME, Duska LR, Cantuaria G, Kavecansky J, Leath CA 3rd, Powell M, Cadungog MG, Rose PG, Kim YM, Huang HQ, Provencher M, Wenzel LB, Bookman MA, Kohn EC, Secord AA. Lee JM, et al. Among authors: leath ca 3rd. J Clin Oncol. 2024 Dec 20;42(36):4305-4316. doi: 10.1200/JCO.24.00683. Epub 2024 Oct 3. J Clin Oncol. 2024. PMID: 39361946 Clinical Trial.
Health disparities in cervical cancer: Estimating geographic variations of disease burden and association with key socioeconomic and demographic factors in the US.
Castellano T, ElHabr AK, Washington C, Ting J, Zhang YJ, Musa F, Berksoy E, Moore K, Randall L, Chhatwal J, Ayer T, Leath CA 3rd. Castellano T, et al. Among authors: leath ca 3rd. PLoS One. 2024 Jul 18;19(7):e0307282. doi: 10.1371/journal.pone.0307282. eCollection 2024. PLoS One. 2024. PMID: 39024212 Free PMC article.
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Pitiyarachchi O, Ansell PJ, Coleman RL, Dinh MH, Holman L, Leath CA 3rd, Werner T, DiSilvestro P, Morgan M, Tew W, Lee C, Cunningham M, Newton M, Edraki B, Lim P, Barlin J, Spirtos NM, Tewari KS, Edelson M, Reid T, Carlson J, Friedlander M. Pitiyarachchi O, et al. Among authors: leath ca 3rd. Gynecol Oncol. 2024 Aug;187:221-226. doi: 10.1016/j.ygyno.2024.05.021. Epub 2024 May 30. Gynecol Oncol. 2024. PMID: 38821039 Free article. Clinical Trial.
Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.
Kopelman ZA, Tian C, Tumas J, Phippen NT, Tarney CM, Hope ER, Winkler SS, Jokajtys S, Kucera CW, Chan JK, Richardson MT, Kapp DS, Hamilton CA, Leath CA 3rd, Jones NL, Rocconi RP, Farley JH, Secord AA, Cosgrove CM, Powell MA, Klopp A, Walker JL, Fleming GF, Bateman NW, Conrads TP, Maxwell GL, Darcy KM. Kopelman ZA, et al. Among authors: leath ca 3rd. Gynecol Oncol. 2024 Apr;183:103-114. doi: 10.1016/j.ygyno.2024.03.026. Epub 2024 Apr 8. Gynecol Oncol. 2024. PMID: 38593674
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279.
Horowitz NS, Deng W, Peterson I, Mannel RS, Thompson S, Lokich E, Myers T, Hanjani P, O'Malley DM, Chung KY, Miller DS, Ueland FR, Dizon DS, Miller A, Mayadev JS, Leath CA 3rd, Monk BJ. Horowitz NS, et al. Among authors: leath ca 3rd. J Clin Oncol. 2024 Jun 1;42(16):1914-1921. doi: 10.1200/JCO.23.02235. Epub 2024 Apr 4. J Clin Oncol. 2024. PMID: 38574312 Clinical Trial.
Immuno-Molecular Targeted Therapy Use and Survival Benefit in Patients with Stage IVB Cervical Carcinoma in Commission on Cancer®-Accredited Facilities in the United States.
Sitler CA, Tian C, Hamilton CA, Richardson MT, Chan JK, Kapp DS, Leath CA 3rd, Casablanca Y, Washington C, Chappell NP, Klopp AH, Shriver CD, Tarney CM, Bateman NW, Conrads TP, Maxwell GL, Phippen NT, Darcy KM. Sitler CA, et al. Among authors: leath ca 3rd. Cancers (Basel). 2024 Mar 6;16(5):1071. doi: 10.3390/cancers16051071. Cancers (Basel). 2024. PMID: 38473428 Free PMC article.
Survival disparities in non-Hispanic Black and White cervical cancer patients vary by histology and are largely explained by modifiable factors.
Kucera CW, Chappell NP, Tian C, Richardson MT, Tarney CM, Hamilton CA, Chan JK, Kapp DS, Leath CA 3rd, Casablanca Y, Rojas C, Sitler CA, Wenzel L, Klopp A, Jones NL, Rocconi RP, Farley JH, O'Connor TD, Shriver CD, Bateman NW, Conrads TP, Phippen NT, Maxwell GL, Darcy KM. Kucera CW, et al. Among authors: leath ca 3rd. Gynecol Oncol. 2024 May;184:224-235. doi: 10.1016/j.ygyno.2024.02.005. Epub 2024 Feb 10. Gynecol Oncol. 2024. PMID: 38340648 Free PMC article.
136 results